BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 38844946)

  • 1. CAPN2 promotes apalutamide resistance in metastatic hormone-sensitive prostate cancer by activating protective autophagy.
    Qi Z; Bai X; Wu L; Zhang P; Guo Z; Yu Y
    J Transl Med; 2024 Jun; 22(1):538. PubMed ID: 38844946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apalutamide in combination with autophagy inhibitors improves treatment effects in prostate cancer cells.
    Eberli D; Kranzbühler B; Mortezavi A; Sulser T; Salemi S
    Urol Oncol; 2020 Aug; 38(8):683.e19-683.e26. PubMed ID: 32466878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The development of apalutamide for the treatment of prostate cancer.
    Isaacsson Velho P; Tofani Sant' Anna P; Pereira da Silva RF; Dal Ponte Ferreira R; Venero FC
    Expert Opin Drug Discov; 2021 Mar; 16(3):217-226. PubMed ID: 33003959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer.
    Dellis AE; Papatsoris AG
    Expert Opin Investig Drugs; 2018 Jun; 27(6):553-559. PubMed ID: 29856649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocol for CHAMPION study: a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen deprivation therapy.
    Wang B; Pan J; Zhang T; Ni X; Wei Y; Li X; Fang B; Hu X; Gan H; Wu J; Wang H; Ye D; Zhu Y
    BMC Cancer; 2024 May; 24(1):643. PubMed ID: 38796422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.
    Tan Y; Wang L; Du Y; Liu X; Chen Z; Weng X; Guo J; Chen H; Wang M; Wang X
    Int J Oncol; 2018 Dec; 53(6):2503-2517. PubMed ID: 30272279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
    Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A
    Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy resistance and metastasis-promoting effects of thyroid hormone in hepatocarcinoma cells are mediated by suppression of FoxO1 and Bim pathway.
    Chi HC; Chen SL; Cheng YH; Lin TK; Tsai CY; Tsai MM; Lin YH; Huang YH; Lin KH
    Cell Death Dis; 2016 Aug; 7(8):e2324. PubMed ID: 27490929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Riluzole induces AR degradation via endoplasmic reticulum stress pathway in androgen-dependent and castration-resistant prostate cancer cells.
    Wadosky KM; Shourideh M; Goodrich DW; Koochekpour S
    Prostate; 2019 Feb; 79(2):140-150. PubMed ID: 30280407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endoplasmic reticulum stress, autophagic and apoptotic cell death, and immune activation by a natural triterpenoid in human prostate cancer cells.
    Johnson BM; Radwan FFY; Hossain A; Doonan BP; Hathaway-Schrader JD; God JM; Voelkel-Johnson CV; Banik NL; Reddy SV; Haque A
    J Cell Biochem; 2019 Apr; 120(4):6264-6276. PubMed ID: 30378157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Evaluation of FOXO1 as a Tumor Suppressor in Prostate Cancer.
    Yang N; Wu J; Zhang T; Yang F; Shao J; He C; Qin L
    Comput Math Methods Med; 2021; 2021():8773423. PubMed ID: 34552661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calpain-2 triggers prostate cancer metastasis via enhancing CRMP4 promoter methylation through NF-κB/DNMT1 signaling pathway.
    Gao X; Mao YH; Xiao C; Li K; Liu W; Li LY; Pang J
    Prostate; 2018 Jun; 78(9):682-690. PubMed ID: 29601651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer.
    Ma L; Yan Y; Bai Y; Yang Y; Pan Y; Gang X; Karnes RJ; Zhang J; Lv Q; Wu Q; Huang H
    Theranostics; 2019; 9(17):5020-5034. PubMed ID: 31410199
    [No Abstract]   [Full Text] [Related]  

  • 14. Apalutamide and its use in the treatment of prostate cancer.
    Borno HT; Small EJ
    Future Oncol; 2019 Feb; 15(6):591-599. PubMed ID: 30426794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fenofibrate inhibits the growth of prostate cancer through regulating autophagy and endoplasmic reticulum stress.
    Tao T; Zhao F; Xuan Q; Shen Z; Xiao J; Shen Q
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2685-2689. PubMed ID: 30098788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)].
    Merseburger AS; Suttmann H
    Aktuelle Urol; 2021 Apr; 52(2):155-160. PubMed ID: 33113571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
    Saad F; Cella D; Basch E; Hadaschik BA; Mainwaring PN; Oudard S; Graff JN; McQuarrie K; Li S; Hudgens S; Lawson J; Lopez-Gitlitz A; Yu MK; Smith MR; Small EJ
    Lancet Oncol; 2018 Oct; 19(10):1404-1416. PubMed ID: 30213449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.
    Shen H; Wang D; Li L; Yang S; Chen X; Zhou S; Zhong S; Zhao J; Tang J
    Gene; 2017 Jan; 596():110-118. PubMed ID: 27746366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
    Chi KN; Agarwal N; Bjartell A; Chung BH; Pereira de Santana Gomes AJ; Given R; Juárez Soto Á; Merseburger AS; Özgüroğlu M; Uemura H; Ye D; Deprince K; Naini V; Li J; Cheng S; Yu MK; Zhang K; Larsen JS; McCarthy S; Chowdhury S;
    N Engl J Med; 2019 Jul; 381(1):13-24. PubMed ID: 31150574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autophagy pathway is required for IL-6 induced neuroendocrine differentiation and chemoresistance of prostate cancer LNCaP cells.
    Chang PC; Wang TY; Chang YT; Chu CY; Lee CL; Hsu HW; Zhou TA; Wu Z; Kim RH; Desai SJ; Liu S; Kung HJ
    PLoS One; 2014; 9(2):e88556. PubMed ID: 24551118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.